Equites Radar

ATEC · Alphatec Holdings, Inc.

Medical DevicesUnited StatesAnalyst view: Strong Buy

$8.67

+7.50% last session

End-of-day data · updated 2026-07-29

Mildly bearish1 bullish · 3 bearish technical signals
Consensus: Strong Buy (1.23 from 14 analysts)
To mean target: +82.9%

Market cap

$1B

Enterprise value

$2B

Trailing P/E

Forward P/E

15.8

Dividend yield

Beta

0.85

Avg volume

3M

Employees

1K

2D change

7.50%

5D change

12.83%

10D change

9.13%

30D change

-1.89%

60D change

20.26%

MTD change

5.19%

YTD change

-55.70%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.23
Covering analysts14
Mean price target$15.86
Low price target$11.00
Upside to mean target+82.9%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)57.7
50-day MA$8.50
200-day MA$13.62
Price vs 50-day MA+9.7%
Price vs 200-day MA-31.6%
MACD histogram-0.03
Volume vs 3-month avg0.6×
52w low $6.9952w high $22.68

Analyst sentiment over time — ATEC

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-28

Latest call per bank · past 12 months

UBS

Buy

$15.00

+73.0% vs price
▲ raised from $0.00Initiates · 2026-07-28

Barclays

Overweight

$24.00

+176.8% vs price
▼ cut from $27.00Maintains · 2026-05-07

Wells Fargo

Overweight

$14.00

+61.5% vs price
▼ cut from $28.00Maintains · 2026-05-07

JP Morgan

Overweight

$16.00

+84.5% vs price
▼ cut from $24.00Maintains · 2026-05-06

Morgan Stanley

Equal-Weight

$21.00

+142.2% vs price
▲ raised from $16.00Maintains · 2025-11-10

Recent rating actions

DateFirmActionRatingPrice target
2026-07-28UBSInitiatesBuy$0.00 $15.00
2026-07-23Stephens & Co.InitiatesOverweight$0.00 $15.00
2026-07-09BMO CapitalInitiatesOutperform$0.00 $11.00
2026-07-08StifelMaintainsBuy$16.00 $13.00
2026-05-07BarclaysMaintainsOverweight$27.00 $24.00
2026-05-07Wells FargoMaintainsOverweight$28.00 $14.00
2026-05-07HC Wainwright & Co.ReiteratesBuy$24.00
2026-05-06Canaccord GenuityMaintainsBuy$25.00 $23.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 9.7% above the 50-day MA ($8.50).
  • Price vs 200-day MA: Trading 31.6% below the 200-day MA ($13.62).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($6.99) and high ($22.68).

ATEC Price Chart

Loading chart for ATEC

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$-0.04
Net debt / EBITDA16.3
WACC8.0%
Revenue growth14.00%
Earnings growth

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

More in Medical Devices

Screen ATEC against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.